DBV Technologies
$ 17.41
5.29%
12 Jun - close price
- Market Cap 978,948,000 USD
- Current Price $ 17.41
- High / Low $ 17.73 / 16.37
- Stock P/E N/A
- Book Value 3.52
- EPS -4.50
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.66 %
- ROE -1.59 %
- 52 Week High 26.18
- 52 Week Low 8.50
About
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.
Analyst Target Price
$40.45
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-03-27 | 2025-10-28 | 2025-07-29 | 2025-04-30 | 2025-03-27 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-03-07 | 2023-10-31 | 2023-07-31 |
| Reported EPS | -0.09 | -0.1994 | -0.21 | -0.27 | -0.23 | -0.2126 | -1.49 | -1.57 | -5.2 | -0.0581 | -1.61 | -2.36 |
| Estimated EPS | -0.17 | -0.1886 | -0.29 | -0.16 | -0.22 | -0.21 | -1.64 | -2.65 | -2.06 | -0.23 | -2.63 | -2.27 |
| Surprise | 0.08 | -0.0108 | 0.08 | -0.11 | -0.01 | -0.0026 | 0.15 | 1.08 | -3.14 | 0.1719 | 1.02 | -0.09 |
| Surprise Percentage | 47.0588% | -5.7264% | 27.5862% | -68.75% | -4.5455% | -1.2381% | 9.1463% | 40.7547% | -152.4272% | 74.7391% | 38.7833% | -3.9648% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.09 |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DBVT
2026-06-12 11:39:56
DBV Technologies stock rebounded by nearly 2% to €2.88, extending a recovery from its €2.75 support despite a significant monthly decline of 17.44%. The rebound follows positive data from its phase 3 VITESSE study and presentation of the phase 2 THRIVE study protocol. While still below key moving averages, the technical recovery is supported by good clinical news.
2026-06-11 17:15:00
DBV Technologies stock rebounded by 2.47% to €2.82, finding support at the €2.75 level after a significant decline. This rebound follows the release of positive data from its Phase 3 VITESSE study for a peanut allergy patch, with an RSI indicating seller exhaustion. The company also plans to present its Phase 2 THRIVE study protocol at an upcoming immunology congress.
2026-06-09 10:38:55
DBV Technologies announced a revision to its participation in the Goldman Sachs 47th Annual Global Healthcare Conference. The article is a brief news update from Reuters. Further details were not provided in the snippet.
2026-06-09 10:38:55
DBV Technologies stock fell over 2% at mid-session, breaking a key technical support level of €2.84, despite a generally positive Parisian market. This decline occurred while its CEO was speaking at the Goldman Sachs Global Healthcare conference. The company recently announced positive data from its phase 3 VITESSE study, yet increased short interest indicates growing bearish pressure.
2026-06-08 20:09:46
DBV Technologies announced positive new data from its Phase 3 VITESSE study, showing their VIASKIN Peanut Patch significantly reduced allergic reactions in peanut-allergic children aged 4-7, particularly those with comorbid conditions like asthma, other food allergies, or atopic dermatitis. The company also previewed the design of its Phase 2 THRIVE study, which will explore the patch's efficacy in infants aged 6-12 months for achieving ad lib peanut consumption after three years. These findings will be presented at the EAACI Congress 2026, highlighting the potential versatility and clinical value of the VIASKIN Peanut Patch for different patient populations.
2026-06-08 16:35:00
DBV Technologies announced new positive data from its Phase 3 VITESSE study for the VIASKIN® Peanut Patch, showing statistically significant efficacy in children with peanut allergy and common atopic conditions. The company will present these findings and preview its initiated Phase 2 THRIVE study, which will explore the patch's efficacy in infants aged 6-12 months, at the EAACI Congress 2026. These studies reinforce confidence in the VIASKIN® Peanut Patch as a potential non-invasive treatment option across various patient populations with peanut allergy.
